Influence of camel milk on the hepatitis C virus burden of infected patients - PubMed (original) (raw)

Influence of camel milk on the hepatitis C virus burden of infected patients

Esmail Mohamad El-Fakharany et al. Exp Ther Med. 2017 Apr.

Abstract

Hepatitis C virus (HCV) infection represents a world health problem and no protective vaccine or effective drug currently exists. For economic reasons, many patients use traditional medicines to control the infection. In Egypt, camel milk is one of the traditional medicines widely consumed by patients infected with HCV. The present study aimed to evaluate the efficacy of camel milk in the treatment of patients infected with HCV. Whole camel milk from a local farm was administered to patients for 4 months (250 ml/day/patient). Patient sera were collected prior to and following camel milk drinking, and three markers were set-up for sera-evaluation. The three markers indicating the effect of camel milk on HCV infection were: Liver function assays [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]; a viral load assay; and anti-HCV antibodies profile and isotyping against synthetic HCV epitopes. Camel milk demonstrated the ability to improve general fatigue, health and liver function (ALT and AST levels); ALT was reduced in ~88% of patients and AST was reduced in all patients subsequent to drinking camel milk for four months. The majority of patients responded positively to camel milk treatment; RNA viral load decreased in 13 out of the 17 patients (76.47%) and one patient exhibited undetected viremia following camel milk treatment. The anti-HCV antibodies profile and isotyping were significantly decreased (P<0.05) in immunoglobulin (Ig)G1 following treatment in 70-76% of patients. However, the treatment was ineffective in 23.53% of patients who experienced no reduction in RNA viral load following treatment with camel milk. In conclusion, whole camel milk treatment demonstrated efficacy in vivo; the viral load in the majority of patient sera was reduced and the IgG isotype profile was converted to Th1 immunity.

Keywords: alternative medicine; camel milk; hepatitis C virus; infected patients.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Analysis of anti-HCV antibody isotypes following camel milk treatment. (A) The percentage of patients with elevated antibody response to each HCV antigen following treatment. (B) The percentage of patients with decreased antibody response to each HCV antigen prior to treatment. HCV, hepatitis C virus; Ig, immunoglobulin.

References

    1. Williams R. Global challenges in liver disease. Hepatology. 2006;44:521–526. doi: 10.1002/hep.21347. - DOI - PubMed
    1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567. doi: 10.1016/S1473-3099(05)70216-4. - DOI - PubMed
    1. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107–115. doi: 10.1111/j.1365-2893.2006.00785.x. - DOI - PubMed
    1. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the united states, 2003–2013. Clin Infect Dis. 2016;62:1287–1288. doi: 10.1093/cid/ciw111. - DOI - PMC - PubMed
    1. Chung RT. Acute hepatitis C virus infection. Clin Infect Dis. 2005;41(Suppl 1):S14–S17. doi: 10.1086/429490. - DOI - PubMed

LinkOut - more resources